[go: up one dir, main page]

WO2005051353A8 - Formulations pharmaceutiques - Google Patents

Formulations pharmaceutiques

Info

Publication number
WO2005051353A8
WO2005051353A8 PCT/IB2004/003746 IB2004003746W WO2005051353A8 WO 2005051353 A8 WO2005051353 A8 WO 2005051353A8 IB 2004003746 W IB2004003746 W IB 2004003746W WO 2005051353 A8 WO2005051353 A8 WO 2005051353A8
Authority
WO
WIPO (PCT)
Prior art keywords
voriconazole
pharmaceutical formulations
formulation
poloxamers
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2004/003746
Other languages
English (en)
Other versions
WO2005051353A3 (fr
WO2005051353A2 (fr
Inventor
Michael John Humphrey
Tobin Andrew Payne-Cook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Ltd Great Britain
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Ltd Great Britain
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Ltd Great Britain, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of WO2005051353A2 publication Critical patent/WO2005051353A2/fr
Publication of WO2005051353A3 publication Critical patent/WO2005051353A3/fr
Publication of WO2005051353A8 publication Critical patent/WO2005051353A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne une nouvelle formulation pharmaceutique de voriconazole, notamment une formulation renfermant un ou plusieurs poloxamères.
PCT/IB2004/003746 2003-11-25 2004-11-12 Formulations pharmaceutiques Ceased WO2005051353A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0327390A GB0327390D0 (en) 2003-11-25 2003-11-25 Pharmaceutical formulations
GB0327390.1 2003-11-25

Publications (3)

Publication Number Publication Date
WO2005051353A2 WO2005051353A2 (fr) 2005-06-09
WO2005051353A3 WO2005051353A3 (fr) 2005-10-27
WO2005051353A8 true WO2005051353A8 (fr) 2006-05-18

Family

ID=29797775

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/003746 Ceased WO2005051353A2 (fr) 2003-11-25 2004-11-12 Formulations pharmaceutiques

Country Status (2)

Country Link
GB (1) GB0327390D0 (fr)
WO (1) WO2005051353A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2027850A1 (fr) * 2007-08-22 2009-02-25 Sandoz AG Compositions pharmaceutiques contenant du voriconazole
CN101444510B (zh) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 含有伏立康唑的药物制剂及其制备方法
CA2872958A1 (fr) * 2012-05-11 2013-11-14 Cipla Limited Composition pharmaceutique
CN104188904B (zh) * 2014-09-28 2017-02-22 湖北工业大学 一种伏立康唑眼用纳米结晶制剂及其制备方法
CN113662914A (zh) * 2021-08-25 2021-11-19 兆科药业（合肥）有限公司 一种含伏立康唑的眼用凝胶剂及其制备方法与应用
PL247580B1 (pl) * 2023-02-09 2025-07-28 Univ Medyczny Im Piastow Slaskich We Wroclawiu Kompozycja farmaceutyczna z flukonazolem o zwiększonej aktywności przeciwgrzybiczej, postać kompozycji farmaceutycznej oraz zastosowanie kompozycji farmaceutycznej

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9713149D0 (en) * 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
GB2359747B (en) * 2000-02-29 2002-04-24 Maelor Pharmaceuticals Ltd Anaesthetic formulations
HUP0501030A3 (en) * 2000-12-22 2008-04-28 Baxter Int Method for preparing submicron particle suspensions

Also Published As

Publication number Publication date
WO2005051353A3 (fr) 2005-10-27
WO2005051353A2 (fr) 2005-06-09
GB0327390D0 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
MXPA03007215A (es) Formulaciones farmaceuticas.
AP2405A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms.
IL173571A0 (en) Injectable, oral, or topical sustained release pharmaceutical formulations
EP1631239A4 (fr) Compositions pharmaceutiques contenant des composes actifs de vitamine d
MXPA03006884A (es) Formulacion farmaceutica.
DK1615646T4 (da) Farmaceutiske formuleringer, der indeholder methylnaltrexon
NO20052306D0 (no) Dispergerbare farmasoytiske blandinger.
GB0302671D0 (en) Pharmaceutical formulations
MXPA03007641A (es) Formulacion farmaceutica.
WO2006074398A3 (fr) Formulations pharmaceutiques a liberation prolongee
IL172824A0 (en) Pharmaceutical formulations
WO2010046061A3 (fr) Préparations cosmétiques et/ou pharmaceutiques
EP1620112A4 (fr) Desmogleine 4, nouveau gene de la croissance des cheveux
GB0302672D0 (en) Pharmaceutical formulations
WO2005030142A3 (fr) Formulations de rifalazil
WO2006056696A3 (fr) 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
WO2005051353A3 (fr) Formulations pharmaceutiques
WO2005060981A3 (fr) Compositions pharmaceutiques
GB0316341D0 (en) Pharmaceutical formulations
HU0304095D0 (en) Novel, effective pharmaceutical compositions
ITTO20030850A1 (it) Procedimento per la preparazione di 4-ammino-3,5-dicloro-benzotrifloruro.
IL172304A0 (en) Pharmaceutical compositions comprising active vitamin d compounds
ZA200204905B (en) Improved pharmaceutical dental formulations.
AU2003283508A1 (en) .pharmaceutical composition comprising htless thansbgreater than4less than/sbgreater thandless thanspgreater than100less than/spgreater thana receptors, and therapeutic uses thereof
GB0316335D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WR Later publication of a revised version of an international search report
NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct app. not ent. europ. phase